Amgen Rare Disease
Presence
Amgen is one of the...
Amgen is a company listed under the stock ticker AMGN (US).
Amgen has a direct presence in 21 countries.Amgen has 24 subsidiaries including Amgen APAC, Amgen Argentina and Amgen Australia.
They are in:
- Pharmaceuticals84%
- Biotechnology16%
Acquisition, funding and merger involving Amgen.
- Amgen Rare Disease and Amgen have announced they will merge (posted on October 10 2023)..
- Amgen has announced the acquisition of Amgen Rare Disease (posted on December 12 2022).
Executives
View the org chart displaying its 10 main executives
Most searched biographies at Amgen Rare Disease
- Vikram Karnani, Executive Vice President and President, Global Com...
- Barry Ivin, Vice President, Manufacturing and Site Leader
- Jack Danilkowicz, Senior Vice President, Commercial Strategy and G...
Popular executive movements at Amgen Rare Disease
- Susan Mahony, Director, has left the company (posted on October 11 2023).
- Jeff Himawan, Director, has left the company (posted on October 11 2023).
- William Daniel, Director, has left the company (posted on October 11 2023).
Popular executive movements at Amgen
- David Reese, who was Executive Vice President of Research and Development, is promoted to Executive Vice President and Chief Technology Officer (posted on December 14 2023).
- James Bradner has joined the company as Executive Vice President, Research and Development and Chief Scientific Officer (posted on December 14 2023).
Create your alert
to follow the executive moves at Amgen Rare Disease.
Pharmaceuticals
Amgen has 1,860 competitors including Pfizer (United States (USA)), Sanofi (France) and Johnson & Johnson (United States (USA)).
Popular M&A news in Pharmaceuticals
- MedMen has filed for bankruptcy protection (posted on April 28 2024).
- AstraZeneca has announced the acquisition of Fusion Pharma (posted on March 23 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (posted on March 19 2024).
Popular contacts in Pharmaceuticals
News
Press releases by Amgen Rare Disease
- Horizon Therapeutics plc Announces New Development Programs at Virtual R&D Day | Horizon Therapeutics plc
- Horizon Therapeutics plc Announces Agenda for Virtual R&D Day for Investors and Analysts on Sept. 29, 2021 | Horizon Therapeutics plc
- Horizon Therapeutics plc Announces Data Showing UPLIZNA® (inebilizumab-cdon) Also Produces Rapid and Sustained B-Cell Depletion in African Americans with Neuromyelitis Optica Spectrum Disorder (NMOSD) | Horizon Therapeutics plc
- Horizon Therapeutics plc Announces New Genetic Counselor Curated Algorithms and Next-Generation Sequencing Data as Winning Solutions of First-Ever Horizon Prize, Powered by MIT Solve, to Accelerate Rare Disease Diagnosis | Horizon Therapeutics plc
- Horizon Therapeutics plc Named One of the 2021 Best Workplaces for Women™ by Fortune and Great Place to Work® | Horizon Therapeutics plc
- Horizon Therapeutics plc Initiates Randomized Controlled Clinical Trial Evaluating TEPEZZA® (teprotumumab-trbw) for the Treatment of Chronic (Inactive) Thyroid Eye Disease (TED) | Horizon Therapeutics plc
- Horizon Therapeutics plc Named One of PEOPLE’s 100 Companies That Care® | Horizon Therapeutics plc
- RSS News Feeds | Horizon Therapeutics plc
- Horizon Therapeutics plc to Participate in Upcoming Conferences | Horizon Therapeutics plc
- Press Releases | Horizon Therapeutics plc
- View more press releases Close
Social media about Amgen Rare Disease
- Amgen Rare Disease on Wikipedia, Google News & Yahoo Finance
- Amgen Rare Disease on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Vikram Karnani 
Call Amgen Rare Disease at +1 224...
